Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a milk protein replace opioids after C-Section?

NCT ID NCT07502235

Symptom relief Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether lactoferrin, a natural protein found in milk, can help manage pain after a cesarean section. Ninety women having planned C-sections will receive either lactoferrin or a placebo before and after surgery, alongside standard painkillers. The goal is to see if lactoferrin reduces pain intensity and the need for opioid medications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lactoferrin
What this could lead to
If it works, this could offer a natural way to reduce pain and opioid use after C-sections, helping mothers recover faster.
What could go wrong
This is a small, early-phase trial. The effect may be small or no better than placebo, and results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Referred to elective (non-emergency) cesarean section * Undergoing spinal anesthesia) with American Society of Anesthesiologists (ASA) classification I and II * Term gestational age Exclusion Criteria: * History of seizures * Pre-eclampsia or eclampsia * Hypertension * Use of narcotic painkillers for 24 h before the intervention * Medications inducing neuropathy including Amiodarone, Metronidazole, Phenytoin \& Colchicine. * Prolongation of cesarean section (more than 1.5 h) * Increase in the size of the incision * Occurrence of any unusual complication during surgery, * Failure of spinal anesthesia and its conversion to general anesthesia * Contraindications to spinal anesthesia * Use of interacting medication: fluoroquinolones, loratadine, fexofenadine, alvimopan, armodafinil

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cesarean birth are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cesarean birth Post operative analgesia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mansoura Hospital

    Cairo, 11856, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.